All In Biotech

Drug Trial Radar · NCT06811233

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

May 8, 2025

Primary completion

Aug 31, 2029

Study completion Aug 31, 2031

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Congressionally Directed Medical Research Programs
First posted
Feb 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate \[Ca-EDTA\] and dimercaptosuccinic acid \[DMSA\]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy alone. Researchers think lowering the level of metals found in the blood/bone marrow may help to control the disease and/or improve the response to chemotherapy.

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

  • DMSADrug

    Given PO

  • Ca-EDTADrug

    Given by IV

  • Magnesium SulfateDrug

    Given by infusion

  • MultivitaminDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Adverse Events (AEs)Time frame: Through study completion; an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.